Pharmacy Technician Pulse

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

tag narcolepsy

PharmaShots Weekly Snapshots (May 01 - 05, 2023)

PharmaShots

MAY 5, 2023

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive EC’s Marketing Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease Date: May 05, 2023 | Tags: Chiesi Global Rare Diseases, Protalix BioTherapeutics, PRX-102, pegunigalsidase alfa, Fabry Disease, Regulatory, EC, Marketing Authorization Kinoxis Therapeutics (..)

FDA

Axsome bounces back as FDA clears depression drug

pharmaphorum

AUGUST 21, 2022

There’s no word yet on its pricing, but for comparison Spravato was launched with an annual price tag of around $32,400, which the Institute for Clinical and Economic Review (ICER) concluded was around 25% to 52% too high to be cost effective. Following after is AXS-12 (reboxetine) for narcolepsy, which could be filed in 2023.

FDA

FDA Labelling

PharmaShots Weekly Snapshots (May 01 - 05, 2023)

Axsome bounces back as FDA clears depression drug

Stay Connected